NASDAQ: NLSPNls Pharmaceutics Ltd Stock
$1.47-0.06 (-3.92%)
Updated Apr 30, 2025
NLSP Price
$1.47
Fair Value Price
-$0.02
Market Cap
$1.45M
52 Week Low
$1.30
52 Week High
$18.39
P/E
-0.22x
P/B
-0.16x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.60M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.13
Operating Cash Flow
-$4M
Beta
0.36
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NLSP Overview
NLS Pharmaceutics AG is developing therapies for patients with rare and complex central nervous system disorders (e.g., narcolepsy, idiopathic hypersomnia, and other rare sleep disorders), as well as neurodevelopmental disorders (e.g, attention deficit hyperactivity disorder). The company's lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy, and Nolazol for the treatment of ADHD. NLS Pharmaceutics was incorporated in 2015 and is based in Zurich, Switzerland.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NLSP's potential to beat the market
- NLSP doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
NLSP
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important NLSP news, forecast changes, insider trades & much more!
NLSP News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NLSP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NLSP ($1.47) is overvalued by 7,734.52% relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
NLSP ($1.47) is not significantly undervalued (7,734.52%) relative to our estimate of its Fair Value price of -$0.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
NLSP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NLSP due diligence checks available for Premium users.
Valuation
NLSP fair value
Fair Value of NLSP stock based on Discounted Cash Flow (DCF)
Price
$1.47
Fair Value
-$0.02
Undervalued by
7,724.15%
NLSP ($1.47) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NLSP ($1.47) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NLSP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NLSP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.22x
Industry
-162.28x
Market
29.18x
NLSP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.16x
Industry
4.45x
NLSP's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
NLSP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$1.2M
Liabilities
$10.5M
Debt to equity
-1.13
NLSP's short-term liabilities ($7.72M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NLSP's long-term liabilities ($2.74M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NLSP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NLSP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
NLSP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NLSP vs Biotech Stocks
Nls Pharmaceutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.